Keyword: Perjeta

Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer.

Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.

With biosim rivals looming, Roche will need its newer meds to step up, and Wednesday's Kadcyla data could give its breast cancer franchise a boost.

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

Back in June, England’s cost watchdog refused to recommend Roche’s Perjeta for postsurgery breast cancer patients. And it’s sticking by that decision.

Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.

Roche in July boosted the prices of nine medicines by an average of about 3%, including blockbuster oncology drugs Herceptin, Avastin and Rituxan.

England’s cost watchdogs are blocking reimbursement of Roche's Perjeta for some postsurgery patients with early breast cancer.